Seems to be a promising approach and not only for Covid-19 viral infections!
"... they designed and manufactured various nanoparticles, each with 500 to 2000 ACE2 molecules. SARS-CoV-2 readily bound to these ACE2-bearing nanoparticles. Overall, the nanoparticles were up to 50 times more effective at inhibiting naturally occurring SARS-CoV-2 mutants when compared with soluble recombinant ACE2, which is similar to antibody drugs that are also recombinant proteins. ..."
From the abstract:
"... Decoy nanoparticles—cell-mimicking particles that bind and inhibit virions—are an emerging class of therapeutics that may overcome such drug resistance challenges. ... To address this gap, this study presents a systematic, comparative evaluation of various biologically derived nanoscale vesicles, which may be particularly well suited to sustained or repeated administration in the clinic due to low toxicity, and investigates their potential to inhibit multiple classes of model SARS-CoV-2 virions. A key finding is that such particles exhibit potent antiviral efficacy across multiple manufacturing methods, vesicle subclasses, and virus-decoy binding affinities. In addition, these cell-mimicking vesicles effectively inhibit model SARS-CoV-2 variants that evade mAbs and recombinant protein-based decoy inhibitors. This study provides a foundation of knowledge that may guide the design of decoy nanoparticle inhibitors for SARS-CoV-2 and other viral infections."
Elucidating Design Principles for Engineering Cell-Derived Vesicles to Inhibit SARS-CoV-2 Infection (open access)
No comments:
Post a Comment